



**Press Release**

Thursday, July 30, 2009

Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531  
NSE: STAR

---

## **Financial Performance Q2-2009**

---

### **CONSOLIDATED**

**Revenue from Operations at Rs.309 Crores up 21%, and PAT at Rs. 42 Crores against Net Loss of Rs. 49 Crores in Q2'08**

### **STAND-ALONE**

**Revenue from Operations at Rs. 175 Crores up 9%, and PAT at Rs.60 Crores against Net Loss of Rs.56 Crores in Q2'08**

**Source: Limited Review of Company Financials, IGAAP**

---

Strides Arcolab Limited today announced results of its limited review of financials for the second quarter ended June 30, 2009.

### **Highlights for the quarter**

#### **Consolidated results**

- Revenue from operations at Rs.309.80 crores against Rs.255.40 crores in Q2 '08.
- Operational EBITDA for Q2'09 at Rs 48.20 crores as against Rs 47.80 crores in Q2'08 after excluding Forex loss of Rs.13.70 crores in Q2'09 and Forex gain of Rs.14.10 crores respectively.
- PAT at Rs.41.70 crores in Q2'09 as compared to loss of Rs.48.80 crores in Q2'08 after including Forex impact.

## Stand Alone results

- Revenue from operations at Rs. 175.40 crores as against Rs. 160.80 crores in Q2 '08.
- Operational EBITDA at Rs.34.90 crores, up by 31% in Q2'09 as compared to Rs.26.60 crores in Q2'08 after excluding Forex loss of Rs.15.20 crores in Q2'09 and Forex gain of Rs.9.50 crores in Q2'08.
- PAT at Rs.60.10 crores in Q2'09 as compared to a loss of Rs.56 crores in Q2'08.

## Other Highlights

- Corporate Restructuring announced – to align its global operations into 3 separate entities - Specialty Pharmaceuticals, Pharmaceuticals and R&D.
- Shareholders approved the composite scheme of arrangement for amalgamation of Global Remedies Limited, Grandix Pharmaceuticals Limited, Grandix Laboratories Limited and Quantum Remedies Private Limited with Strides Arcolab Limited. Scheme awaiting approval from the Honorable High Court of Bombay.
- The Company bought back USD 18.50 million aggregate face value USD 100 million Zero Percent Convertible Bonds Due 2012 and USD 2 million aggregate face value USD 40 million – 0.5% Convertible Bonds due 2010.
- The Company has received 2 ANDA approvals from USFDA for Adenosine Injection USP and Meloxicam Tablets USP. Total approvals in Steriles space at 16 and Orals space at 12. Total filings in Sterile Space at 93 and Orals space at 35.
- Promoters subscribed to 6.2 Million convertible warrants which are convertible into equivalent number of equity shares within a period of 18 months.
- Commenced commercial supply of Oseltamivir Capsules for Influenza-A (H1N1) Virus (Swine Flu).

**Commenting on Q2 09 performance, Strides Arcolab's Vice Chairman & Group CEO Mr. Arun Kumar stated “ the results are in line with targets set by the Company and the management is confident that the new reorganization initiative set in motion by the company will reinforce the Operational and Execution focus for continued growth trajectory “**

<b>Qtr-on Qtr (Consolidated) Highlights</b>	<b>Figures in INR Millions</b>		
<b>Particulars</b>	<b>Q-2'09</b>	<b>Q-2'08</b>	<b>Growth</b>
<b>Operational Revenue</b>	<b>3098</b>	<b>2554</b>	<b>21%</b>
<b>Total Revenue</b>	<b>3110</b>	<b>2760</b>	<b>13%</b>
<b>PBT</b>	<b>509</b>	<b>(426)</b>	<b>100+%</b>
<b>PAT (after minority interest)</b>	<b>417</b>	<b>(488)</b>	<b>100+%</b>

Note: Previous period numbers have been recast / restated wherever necessary to conform to the current period classification.

<b>Half year-on Half year (Consolidated) Highlights</b>	<b>Figures in INR Millions</b>		
<b>Particulars</b>	<b>H-1'09</b>	<b>H-1'08</b>	<b>Growth</b>
<b>Operational Revenue</b>	<b>5940</b>	<b>4623</b>	<b>28%</b>
<b>Total Revenue</b>	<b>6026</b>	<b>5030</b>	<b>20%</b>
<b>PBT</b>	<b>620</b>	<b>152</b>	<b>100+%</b>
<b>PAT (after minority interest)</b>	<b>522</b>	<b>37</b>	<b>100+%</b>

Note: Previous period numbers have been recast / restated wherever necessary to conform to the current period classification.

## Strides Overview

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penams, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com)

**For further information, please contact**

Mr. T.S. Rangan, Group CFO Tel: +91 80 6658 0115	Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 9880376648 Email: <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a>  Kasturi Wasmatkar, Corporate Voice/ Weber Shandwick Mobile: +91 9916728393 Email: <a href="mailto:kasturi@corvoshandwick.co.in">kasturi@corvoshandwick.co.in</a>
---	---